{"id":"poractant-alfa-instillation","safety":{"commonSideEffects":[{"rate":null,"effect":"Transient oxygen desaturation"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Reflux of instillate into endotracheal tube"},{"rate":null,"effect":"Pulmonary hemorrhage"}]},"_chembl":{"chemblId":"CHEMBL1201622","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Poractant alfa is derived from porcine lung tissue and contains the key surfactant proteins and lipids necessary for reducing surface tension in the alveoli. By restoring surfactant function, it improves lung compliance, reduces work of breathing, and prevents alveolar collapse, particularly in conditions characterized by surfactant deficiency or dysfunction.","oneSentence":"Poractant alfa is a natural pulmonary surfactant that replaces deficient or dysfunctional surfactant in the lungs to restore normal respiratory function.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:01:51.481Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Respiratory distress syndrome in premature infants"},{"name":"Acute respiratory distress syndrome (ARDS)"}]},"trialDetails":[{"nctId":"NCT07261787","phase":"PHASE4","title":"Duration of Surfactant Administration and Impact on Stabilisation of Vital Parameters in Very Preterm Neonates: 1 Minutes Versus 5 Minutes","status":"NOT_YET_RECRUITING","sponsor":"Medical University of Graz","startDate":"2025-12-01","conditions":"Neonates and Preterm Infants, Infant Respiratory Distress Syndrome, Surfactant Deficiency Syndrome Neonatal","enrollment":76},{"nctId":"NCT06007547","phase":"PHASE4","title":"Prophylactic Minimally Invasive Surfactant Evaluation","status":"RECRUITING","sponsor":"Endeavor Health","startDate":"2024-01-01","conditions":"Respiratory Distress Syndrome, Newborn, Premature Birth","enrollment":200},{"nctId":"NCT03275415","phase":"PHASE4","title":"Intratracheal Budesonide/Surfactant Prevents BPD","status":"COMPLETED","sponsor":"Taipei Medical University","startDate":"2019-07-01","conditions":"Respiratory Distress Syndrome, Bronchopulmonary Dysplasia","enrollment":310},{"nctId":"NCT05711966","phase":"NA","title":"Comparison of INRECSURE and LISA in Preterm Neonates With RDS","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2023-01-09","conditions":"Respiratory Distress Syndrome, Bronchopulmonary Dysplasia","enrollment":381},{"nctId":"NCT01039285","phase":"PHASE4","title":"Exogenous Surfactant in Very Preterm Neonates in Prevention of Bronchopulmonary Dysplasia","status":"COMPLETED","sponsor":"Jean Michel Hascoet","startDate":"2009-12","conditions":"Infant, Premature, Diseases, Respiratory Distress Syndrome, Newborn, Bronchopulmonary Dysplasia","enrollment":118},{"nctId":"NCT02140580","phase":"PHASE4","title":"OPTIMIST-A Trial: Minimally-invasive Surfactant Therapy in Preterm Infants 25-28 Weeks Gestation on CPAP","status":"UNKNOWN","sponsor":"Menzies Institute for Medical Research","startDate":"2011-12","conditions":"Bronchopulmonary Dysplasia","enrollment":486},{"nctId":"NCT01941524","phase":"PHASE4","title":"Brain Oxygenation and Function of Preterm Newborns During Administration of Two Different Surfactant Preparations","status":"COMPLETED","sponsor":"Poznan University of Medical Sciences","startDate":"2013-03-03","conditions":"Respiratory Distress Syndrome, Newborn, Respiratory Failure","enrollment":22},{"nctId":"NCT01306240","phase":"PHASE3","title":"Surfactant Versus Nasal Continuous Positive Airway Pressure (nCPAP) for Respiratory Distress Syndrome in the Newborn ≥ 35 Weeks of Gestation","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2011-03","conditions":"Acute Respiratory Distress Syndrome","enrollment":19}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":56,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Poractant alfa instillation","genericName":"Poractant alfa instillation","companyName":"Poznan University of Medical Sciences","companyId":"poznan-university-of-medical-sciences","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Poractant alfa is a natural pulmonary surfactant that replaces deficient or dysfunctional surfactant in the lungs to restore normal respiratory function. Used for Respiratory distress syndrome in premature infants, Acute respiratory distress syndrome (ARDS).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}